| Bioactivity | XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo[1]. |
| Invitro | XVA143 (1 μM) completely abolishes binding of ICAM-1 to LFA-1 in Mn2+ and Mg2+/EGTA, with no hint of agonism[1].XVA143 restores rolling of the αL-E310A β2 mutant by inducing extension of αL[2]. Cell Viability Assay[1] Cell Line: |
| Name | XVA143 |
| CAS | 264275-77-6 |
| Formula | C25H21Cl2N3O8 |
| Molar Mass | 562.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Azucena Salas, et al. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity. 2004 Apr;20(4):393-406. [2]. Mélanie R Tardif, et al. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob Agents Chemother. 2009 Nov;53(11):4656-66. |